Patents Assigned to Inserm
  • Method for in vitro diagnosis of PVL-producing
    Patent number: 8936791
    Abstract: A method for in vitro diagnosis of Staphylococcus aureus producing Panton-Valentine Leukocidin (PVL), using a biological sample derived from an individual liable to be colonized by or infected with Staphylococcus aureus, wherein the diagnosis is carried out by detection of PVL using a routine immunological test, and the biological sample is pretreated in order to denature the PVL.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: January 20, 2015
    Assignees: Biomerieux, Intstitut National de la Sante et de la Recherche Medicale (Inserm), Universite Claude Bernard Lyon 1 (UCBL)
    Inventors: Cedric Badiou, Jerome Etienne, Gerard Lina, Catherine Ratat
  • ANTI-INFECTIVE COMPOUNDS
    Publication number: 20150018543
    Abstract: The present invention relates to 4H-pyrido[1,2-a]pyrimidin-4-one compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
    Type: Application
    Filed: April 28, 2014
    Publication date: January 15, 2015
    Applicants: Institut Pasteur Korea, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Priscille BRODIN, Thierry CHRISTOPHE, Zaesung NO, Jaeseung KIM, Auguste GENOVESIO, Denis Philippe Cedric FENISTEIN, Heekyoung JEON, Fanny Anne EWANN, Sunhee KANG, Saeyeon LEE, Min Jung SEO, Eunjung PARK, Monica CONTRERAS DOMINGUEZ, Ji Youn NAM, Eun Hye KIM
  • BIOMARKERS OF RENAL DISORDERS
    Publication number: 20150018383
    Abstract: The present invention is directed to the use of marker for Akt2 activation in podocytes as a biomarker to predict toxicity of mTOR inhibitors. Another aspect of the invention relates to a method for preventing graft rejection comprising administering a selective mTORC1 or Akt1 inhibitor in a subject in need thereof.
    Type: Application
    Filed: October 12, 2012
    Publication date: January 15, 2015
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Fabiola Terzi, Guillaume Canaud, Franck Ename
  • Method for manufacturing cubic diamond nanocrystals
    Patent number: 8932553
    Abstract: A method for manufacturing cubic diamond nanocrystals (10) comprising the following successive steps: (a) providing crystalline diamond powder where the maximum particle size of the powder is equal or more than 2 um and equal or less than 1 mm; (b) milling said crystalline micron diamond powder using nitrogen jet milling micronization so as to manufacture a fine powder; (c) nanomilling the fine powder of step b) using a planetary tungsten carbide ball mill; (d) acid treating the nanomilled powder of step c); (e) extracting the cubic diamond nanocrystals (10) by centrifugation. Advantageously round-shaped cubic diamond nanocrystals are manufactured.
    Type: Grant
    Filed: March 8, 2010
    Date of Patent: January 13, 2015
    Assignees: Institut National de la Sante et de la Recherche Medical (INSERM), Armines, Universitaet Stuttgart, Centre National de la Recherche Scientifique
    Inventors: Patrick Curmi, Jean-Paul Boudou, Alain Thorel, Fedor Jelezko, Mohamed Sennour
  • Method to produce light-emitting nano-particles of diamond
    Patent number: 8932554
    Abstract: Method to produce diamonds containing Nitrogen-Vacancy centers from diamonds grown by a high pressure and high temperature process and containing isolated substitutional nitrogen, comprising: —Irradiating (12) said diamonds by an electron beam such that the irradiation dose is comprised between 1017 and 1019 electrons per square centimeter; —annealing (14) the irradiated diamonds in vacuum or in a inert atmosphere at a temperature above 700° C. and for at least 1 hour; characterized in that said electron beam has an acceleration energy above 7 MeV.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: January 13, 2015
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universitat Stuttgart, Armines
    Inventors: Jean-Paul Boudou, Patrick Curmi
  • Methods for the treatment and the diagnosis of cancer
    Patent number: 8933050
    Abstract: The present invention relates to methods for the diagnostic and the staging of cancer such as liver cancer. The present invention also relates to methods for the treatment of cancer including liver cancer such as hepatocellular carcinoma (HCC).
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: January 13, 2015
    Assignees: Institute National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes, Assistance Publique—Hopitaux de Paris
    Inventors: Gérard Friedlander, Laurent Beck, Christine Salaün, Christine Leroy
  • Method of hepatocellular carcinoma classification and prognosis
    Patent number: 8935102
    Abstract: Methodology for the in vitro classification and/or prognosis of hepatocellular carcinoma (HCC) from a HCC sample is based on the determination of the expression profile of particular gene combinations. For example, in one embodiment, a method comprises measuring the expression level in an HCC sample of at least 8 genes selected from the group consisting of: RAB1A, REG3A, NRAS, RAMP3, MERTK, PIR, EPHA1, LAMA3, G0S2, HN1, PAK2, AFP, CYP2C9, CDH2, HAMP, SAE1, ADH6, DCN, FLJ10159, ALDH1L1, IGF1, LECT2, SLC38A1, SPARCL1, CTNNA2, GLUL, LEF1, MATN2, MME, PFN2, SPINT2, TBX3, and FGFR2; b) calculating 6 subgroup distances from the expression profile; and c) classifying the HCC tumor in the subgroup for which the subgroup distance is the lowest, wherein the 6 subgroups G1, G2, G3, G4, G5, and G6 are defined by the presence (+) or absence (?) of their clinical and genetic features.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: January 13, 2015
    Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Jessica Zucman-Rossi, Aurélien De Reynies, David Rickman, Sandrine Boyault
  • USE OF MICRORNA MOLECULES TO INFLUENCE SKIN PIGMENTATION
    Publication number: 20150010485
    Abstract: At least one microRNA selected from among hsa-miR-330, hsa-miR-7 and hsa-miR-137, the mature forms thereof, and the precursors thereof, for depigmenting the skin, and an in vitro method for identifying depigmenting compounds, which includes the steps of: a) placing at least one test compound in contact with a sample of melanocytes; b) measuring the expression or activity of at least one microRNA selected from among miR-330, miR-7 and miR-137, the mature forms thereof, and the precursors thereof, in the melanocytes; c) selecting the compounds for which at least 20% activation of the expression or of the activity of at least one of the microRNAs is measured in the melanocytes treated in a) by an element for comparing with the untreated melanocytes.
    Type: Application
    Filed: December 18, 2012
    Publication date: January 8, 2015
    Applicants: CHANEL PARFUMS BEAUTE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUTE CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS
    Inventors: Gaelle Saintigny, Christian Mahe, Lionel Larue, Florian Rambow
  • Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient
    Publication number: 20150005229
    Abstract: The present invention relates to a compound which is an agonist of the oxytocin receptor o for use in the treatment of a feeding disorder with early-onset. In a particular embodiment, the agonist of the oxytocin receptor is the oxytocin or an active fragment thereof.
    Type: Application
    Filed: August 29, 2014
    Publication date: January 1, 2015
    Applicants: Institut National de la Sante et de la Rechereche Medicale (INSERM), Universite de la Mediterranee, CHU de Toulouse
    Inventors: Francoise Muscatelli, Maithe Tauber, Fabienne Schaller, Denise Thuilleaux
  • METHOD FOR PROGNOSING THE AGE-AT-ONSET OF HUNTINGTON'S DISEASE
    Publication number: 20140377379
    Abstract: The present invention relates to the prediction of the age-at-onset of Huntington's disease. More specifically, it relates to the use of at least one FoxO-centered network related biallelic markers, preferably single nucleotide polymorphism (SNP) markers, in particular GSK-3? and/or TCERG1 and/or FOXO1 and/or FZD10 related biallelic markers, for prognosing the age-at-onset of symptoms of Huntington's disease in an individual at risk of suffering from said disease.
    Type: Application
    Filed: September 2, 2011
    Publication date: December 25, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventor: Christian Neri
  • METHODS FOR ASSESSING ENDOMETRIAL RECEPTIVITY OF A PATIENT AFTER CONTROLLED OVARIAN HYPERSTIMULATION
    Publication number: 20140371092
    Abstract: The present invention relates to methods and kits for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation. More particularly, the invention relates to a method for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation, comprising a step consisting of measuring the expression level of at least one gene selected from fifteen genes in an endometrial biopsy sample obtained from said patient wherein said genes are FGFBP1, MUC20, TM-PRSS3, PRUNE2, HES2, MGST1, ERRFI1, EDN1, SLC17A7, MET, CPT1B, DCDC2, LRRC39, IL18RAP, and FOXP1.
    Type: Application
    Filed: October 22, 2012
    Publication date: December 18, 2014
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER 1
    Inventors: Samir Hamamah, Delphine Haouzi
  • NON HUMAN ANIMAL MODEL FOR ULCERATIVE COLITIS AND ITS MAIN COMPLICATIONS
    Publication number: 20140373186
    Abstract: The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal.
    Type: Application
    Filed: April 13, 2012
    Publication date: December 18, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Eric Ogier-Denis, Xavier Treton, Fanny Daniel, Cecile Guichard, Eric Pedruzzi, Yoram Bouhnik, Yann Harnoy
  • METHOD FOR PREPARING INDUCED PARAXIAL MESODERM PROGENITOR (IPAM) CELLS AND THEIR USE
    Publication number: 20140363886
    Abstract: The present invention relates to an ex vivo method for preparing induced paraxial mesoderm progenitor (iPAM) cells, said method comprising the step of culturing pluripotent cells in an appropriate culture medium comprising an effective amount of an activator of the Wnt signaling pathway and an effective amount of an inhibitor of the Bone Morphogenetic Protein (BMP) signaling pathway.
    Type: Application
    Filed: August 29, 2012
    Publication date: December 11, 2014
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES, UNIVERSITE DE STRASBOURG, CNRS (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE)
    Inventors: Olivier Pourquie, Jérôme Chal
  • Reprogrammation of Eukaryotic Cells with Engineered Microvesicles
    Publication number: 20140356943
    Abstract: The present invention relates to a non-genetic, detergent-free, bacteria-free method for reprogramming a eukaryotic cell, in particular for obtaining induced pluripotent stem cells (iPS), by using engineered microvesicles carrying at least one reprogramming transcription factor, wherein said engineered microvesicles are virus-free.
    Type: Application
    Filed: February 25, 2014
    Publication date: December 4, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Philippe Mangeot, Vincent Lotteau, Marc Peschanski, Mathilde Girard
  • Methods for treating breast cancer
    Patent number: 8900588
    Abstract: The present disclosure is directed to methods of treating and preventing breast cancer or recurrence of breast cancer with compositions comprising anti-progastrin antibodies.
    Type: Grant
    Filed: January 4, 2011
    Date of Patent: December 2, 2014
    Assignees: Les Laboratories Servier, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Jean-François Floch, Leïla Houhou, Françoise Cailler, Dominique Joubert, Frédéric Hollande
  • Inhibitors of cyclophilins and uses thereof
    Patent number: 8901295
    Abstract: The present invention relates to a compound of formula (I): wherein: n is 0, 1 or 2; A is in particular CH or N; X is in particular CO, SO2, CS, and R1 is in particular H, R2 is a group of formula NR3R4 or OR5, R3 and R4 being in particular H, and R5 an alkyl group, R6 is in particular H or an alkyl group, and R7 is in particular an aryl group, for its use in the prevention and/or the treatment of viral pathologies or infections.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: December 2, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Montpellier 1, Universite Paris-EST Creteil val de Marne, Assistance Publique-Hopitaux de Paris, Centre National de la Recherche Scientifique
    Inventors: Jean-Francois Guichou, Lionel Colliandre, Hakim Ahmed-Belkacem, Jean-Michel Pawlotsky
  • IN VITRO MODELLING OF HAEMATOPOIETIC STEM CELL MEDULLARY NESTS: A TOOL FOR STUDYING THE REGULATION OF HAEMATOPOIESIS, EVALUATING THE NESTING POTENTIAL OF A HAEMATOPOIETIC GRAFT AND TESTING THE PHARMACOTOXICOLOGY OF MEDICAMENTS
    Publication number: 20140349312
    Abstract: The present invention relates to a culture support for cultivating hematopoietic stem cells (HSCs) and/or hematopoietic progenitors (HPs), comprising a calcium biomaterial, osteoclasts, endothelial cells and mesenchymatous stem cells (MSCs) and/or osteoblasts and/or adipocytes. The present invention also relates to a method for preparing such a culture support, and an in vitro HSC and/or HP cultivation method. The use of such a culture support for studying cellular mechanisms involved in hematopoiesis and/or differentiation of HSC/HPs and/or for studying the efficacy and/or the toxicity of a medicament candidate is also described.
    Type: Application
    Filed: August 14, 2012
    Publication date: November 27, 2014
    Applicants: Institut Nationalde la Sante et de la Recherche Medicale (INSERM), ETAT FRANCAIS (MINISTERE DE LA DEFENSE), SERVICE DE SANTE DES ARMEES
    Inventors: Jean-Jacques Lataillade, Marie-Caroline Le Bousse-Kerdiles
  • Use of hyaluronic acid for the preparation of compositions intended for improving in particular the protective function of the skin, the eye and the mucous membranes
    Patent number: 8895532
    Abstract: The present invention relates to the use of hyaluronic acid for the preparation of compositions intended for improving the protective function of the skin, the eye and the mucous membranes, in particular of the upper and lower airways and the intestinal mucosa.
    Type: Grant
    Filed: July 4, 2008
    Date of Patent: November 25, 2014
    Assignees: Agro Industrie Recherches et Developpements A.R.D., INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Anthony Bresin, Edith Puchelle, Jean-Marie Zahm, Magali Milliot
  • Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide
    Patent number: 8895520
    Abstract: A method of treatment of a human patient suffering from myeloid neoplasias, includes administrating a therapeutically effective amount of 5-aminoimidazole-4-carboxamide (acadesine), acadesine precursors or acadesine derivatives.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: November 25, 2014
    Assignees: Universite Nice Sophia Antipolis, Centre Hospitalier Universitaire de Nice, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Thomas Cluzeau, Patrick Auberger, Guillaume Robert
  • PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof
    Publication number: 20140335093
    Abstract: The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.
    Type: Application
    Filed: May 20, 2014
    Publication date: November 13, 2014
    Applicants: Universite de la Mediterranee, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventor: Daniel Olive